Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Anti-dsDNA antibodies are a heterogeneous group of antibodies, quite specific for SLE. Their variability is related to the assay used, the immunoglobulin class secondary antibody, and the dsDNA source. The standardization of measuring anti-dsDNA antibodies is still poor and different methods yield different results. Several novel technologies were developed during the last decades that represent viable alternatives to the traditional methods such as the chemiluminescent immunoassay (CIA) and multiplex flow immunoassay (MFI). Additionally, positive results for anti-dsDNA antibodies can be detected in patients with inflammatory arthritis (IA) treated with different biologics reducing its clinical specificity for SLE. Anti-dsDNA antibody levels were evaluated in 246 patient samples: 70 SLE and 176 disease control (including 96 IA during treatment with different biologics), using three enzyme immunoassays (indirect enzyme immunoassay, Bio-Rad Laboratories; chemiluminescent immunoassay, Inova Diagnostics; multiplex flow immunoassay, Bio-Rad Laboratories) and three Crithidia luciliae immunofluorescence tests (CLIFT) (Euroimmun AG, Bio-Rad Laboratories, INOVA Diagnostics). Diagnostic performances were assessed both including and excluding the IA patients. Agreements, measured by the Cohen's Kappa between all methods, ranged from moderate to substantial (0.47-0.68). The clinical sensitivities for the anti-dsDNA antibody tests varied from 5.7% by CLIFT A up to 33.3% provided by EIA wh…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Infantino et al included mainly SLE patients in remission and found a low sensitivity with all assays studied [60].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [60]
In the citing paper
“The specificities reported for CIA from INOVA Diagnostics (3 studies: 89.8%, 96.0%, 97.7% [60], [61], [67]) were higher than those reported from DiaSorin (2 studies: 82.9%, 84.9% [39], [47]), while the reported sensitivities for CIA from DiaSorin (78.6%, 84.6%) were higher than those reported from INOVA (20%, 39.9%, 54.3%) (Table 2).”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [60]
In the citing paper
“The advantages of these multiplex assays are that they are fast, relatively cheap and high-throughput [60], [70].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [60]
In the citing paper
“| INOVA Diagnostics | 95.0 [43.8-100] | 48.7 [8.2-83.0] | 43, 49, 60, 61 | CLIFT |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [60]
In the citing paper
“| INOVA Diagnostics | 96.0 [89.8-97.7] | 39.3 [20.0-54.3] | 60, 61, 67 | CIA |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [60]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519 · cited 3×
“SLICC revised and validated the ACR SLE classification criteria to better adhere to rigorous requisites and gain further awareness about the SLE disease [4].”
BackgroundHochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322 · cited 5×
“Anti-dsDNA antibodies are included in the SLE classification criteria established by the American College of Rheumatology (ACR) [3, 4] which were recently revised by the Systemic Lupus International Collaborating Clinics classification criteria (SLICC) [5].”
BackgroundInfluentialHow to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis
Visser, H., le Cessie, S., Vos, K., Breedveld, F. C., & Hazes, J. M. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10117 · Cited by 731 · cited 1×
“The study included 246 samples from patients suffering from SLE (n = 70) as well as a control group (n = 176), including 96 patients with IA [31], 40 patients with autoimmune thyroiditis, and 40 samples from apparently healthy blood donors.”
BackgroundAgmon-Levin, N., Damoiseaux, J., Kallenberg, C., Sack, U., Witte, T., Herold, M., Bossuyt, X., Musset, L., Cervera, R., Plaza-Lopez, A., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203863 · Cited by 615 · cited 1×
“Therefore, it is recommended that positive results obtained with any screening method should be verified by the Farr method or CLIFT [24].”
MethodThe use of laboratory tests in the diagnosis of SLE
Egner, W. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.6.424 · Cited by 316
Fifty years of anti-ds DNA antibodies: are we approaching journey's end?
Isenberg, D. A., Manson, J. J., Ehrenstein, M. R., & Rahman, A. (2007) · Rheumatology · doi:10.1093/rheumatology/kem112 · Cited by 281
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
Eriksson, C., Engstrand, S., Sundqvist, K.-G., & Rantapää-Dahlqvist, S. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024182 · Cited by 228
BORCHERS, A. T., KEEN, C. L., & GERSHWIN, M. E. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1422.019 · Cited by 208
Mahler, M., Meroni, P.-L., Bossuyt, X., & Fritzler, M. J. (2014) · Journal of Immunology Research · doi:10.1155/2014/315179 · Cited by 203
Updating on the pathogenesis of systemic lupus erythematosus
Gualtierotti, R., Biggioggero, M., Penatti, A. E., & Meroni, P. L. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.007 · Cited by 184 · cited 1×
“Their detection is still ubiquitously used to help diagnose and manage SLE, correlating with disease activity and nephritis [1, 2].”
Backgroundde Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21190 · Cited by 172
Diagnostic criteria for systemic lupus erythematosus: has the time come?
Bertsias, G. K., Pamfil, C. A. M., Fanouriakis, A., & Boumpas, D. T. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.103 · Cited by 145 · cited 1×
“spread technologies, such as FEIA, CIA, and MFI methods [36].”
MethodSHOVMAN, O., GILBURD, B., BARZILAI, O., SHINAR, E., LARIDA, B., ZANDMAN‐GODDARD, G., BINDER, S. R., & SHOENFELD, Y. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.120 · Cited by 114 · cited 11×
“The EIA and MFI methods yielded the highest sensitivity suggesting its potential use as first assay for the SLE screening while CLIFT showed the highest specificity of the anti-dsDNA antibodies in the SLE disease.”
BackgroundInfluentialEilat, D., Hochberg, M., Pumphrey, J. G., & Rudikoff, S. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.489 · Cited by 97 · cited 1×
“Additionally, the ribonucleic acid (RNA) can also constitute an antigen in SLE condition and its corresponding antibody reactivity can be linked to epitopes shared with DNA or not form a separate entity [6, 7].”
BackgroundLinking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus
Giles, B. M., & Boackle, S. A. (2012) · Immunologic Research · doi:10.1007/s12026-012-8345-z · Cited by 95 · cited 1×
“Their detection is still ubiquitously used to help diagnose and manage SLE, correlating with disease activity and nephritis [1, 2].”
BackgroundLe Goff, P., & Saraux, A. (1999) · PubMed · Cited by 81
Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases
Shovman, O., Gilburd, B., Zandman-Goddard, G., Yehiely, A., Langevitz, P., & Shoenfeld, Y. (2005) · Autoimmunity · doi:10.1080/08916930400022707 · Cited by 75 · cited 11×
“The EIA and MFI methods yielded the highest sensitivity suggesting its potential use as first assay for the SLE screening while CLIFT showed the highest specificity of the anti-dsDNA antibodies in the SLE disease.”
BackgroundInfluentialEnocsson, H., Sjöwall, C., Wirestam, L., Dahle, C., Kastbom, A., Rönnelid, J., Wetterö, J., & Skogh, T. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.140677 · Cited by 73 · cited 2×
“Hence, according to the existing literature [18, 39, 41], the current study confirmed that CLIFT is a confirmatory test to detect anti-dsDNA antibodies in SLE patients and that it cannot be used as a screening method for this Ta bl e 3 A ss ay s di ag no st ic pe rf or m an ce”
ResultAntico, A., Platzgummer, S., Bassetti, D., Bizzaro, N., Tozzoli, R., Villalta, D., & Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine (SIMeL) (2010) · Lupus · doi:10.1177/0961203310362995 · Cited by 70
Mähler, M., Radice, A., Yang, W., Bentow, C., Seaman, A., Bianchi, L., & Sinico, R. A. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.01.004 · Cited by 63
Detection of autoantibodies using chemiluminescence technologies
Mahler, M., Bentow, C., Serra, J., & Fritzler, M. J. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1077461 · Cited by 47 · cited 1×
“The principle of the BIO-FLASH system has recently been described [8, 9, 34, 35].”
MethodBiesen, R., Dähnrich, C., Rosemann, A., Barkhudarova, F., Rose, T., Jakob, O., Bruns, A., Backhaus, M., STÖCKER, W., Burmester, G. R., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3250 · Cited by 46 · cited 1×
“Moreover, in the present study, the specificities’ performance was similar while the sensitivities were lower than in our previous study and in other reported studies, probably due to the fact that most of the patients were in clinical remission [16, 39, 40].”
ResultMähler, M., & Dervieux, T. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205324 · Cited by 43 · cited 1×
“In spite of the significant advances in the antidsDNA determination, the current choice of method still varies widely from laboratory to laboratory [38].”
Background(2011) · PubMed · Cited by 41
Infantino, M., Meacci, F., Bentow, C., Martis, P., Benucci, M., Afeltra, A., Rigon, A., Atzeni, F., Sarzi-Puttini, P., Manfredi, M., et al. (2015) · Journal of Immunology Research · doi:10.1155/2015/902821 · Cited by 41 · cited 11×
“The QUANTA Flash dsDNA (Inova Diagnostics Inc., San Diego, CA, USA) assay is a novel CIA that is used on the BIO-FLASH instrument (Biokit s.a., Barcelona, Spain).”
BackgroundMethodInfluentialSelf-citationDetection of antibodies to dsDNA: an overview of laboratory assays
Rouquette, A., & Desgruelles, C. (2006) · Lupus · doi:10.1191/0961203306lu2324oa · Cited by 39
Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies
Pérez, D., Gilburd, B., Cabrera-Marante, Ó., Martínez-Flores, J. A., Serrano, M., Naranjo, L., Pleguezuelo, D., Morillas, L., Shovman, O., Paz-Artal, E., et al. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0241 · Cited by 38
Bentow, C., Lakos, G., Martis, P., Wahl, E., Garcia, M., Viñas, O., Espinosa, G., Cervera, R., Sjöwall, C., Carmona-Fernandes, D., et al. (2016) · Lupus · doi:10.1177/0961203316640917 · Cited by 37 · cited 1×
“The principle of the BIO-FLASH system has recently been described [8, 9, 34, 35].”
MethodAnti-TNFalpha blockers, autoantibodies and autoimmune diseases
Caramaschi, P., Bambara, L. M., Pieropan, S., Tinazzi, I., Volpe, A., & Biasi, D. (2009) · Joint Bone Spine · doi:10.1016/j.jbspin.2008.12.008 · Cited by 36
Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies
GHIRARDELLO, A., VILLALTA, D., MOROZZI, G., AFELTRA, A., GALEAZZI, M., GERLI, R., MATHIEU, A., MERONI, P. L., MIGLIORINI, P., RADICE, A., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1398.045 · Cited by 35 · cited 1×
“Hence, according to the existing literature [18, 39, 41], the current study confirmed that CLIFT is a confirmatory test to detect anti-dsDNA antibodies in SLE patients and that it cannot be used as a screening method for this Ta bl e 3 A ss ay s di ag no st ic pe rf or m an ce”
ResultLaunay, D., Schmidt, J., Lepers, S., Mirault, T., Lambert, M., Kyndt, X., Reumaux, D., Duhamel, A., Hachulla, E., Hatron, P.-Y., et al. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.03.016 · Cited by 35
Measurement of low avidity anti-dsDNA by the Crithidia luciliae test and the PEG assay.
Smeenk, R. J. T., van der Lelij, G., & Aarden, L. A. (1982) · PubMed · Cited by 31
Fiegel, F., Buhl, A., Jaekel, H.-P., Werle, E., Schmolke, M., Ollert, M., & Luppa, P. (2010) · Lupus · doi:10.1177/0961203310369681 · Cited by 24 · cited 1×
“methods used in the modern autoimmune laboratory scenario is still without a specific international consensus on exclusive methods [18–20], and the assays are different in term of class, avidity, affinity, complement fixing ability, antigenic specificity, substrate differences, and cross-reactive pattern of the antibo…”
Methodde Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A. (2017) · Rheumatology · doi:10.1093/rheumatology/kew462 · Cited by 24
Hillebrand, J., Moens, H. B., & Mulder, A. (2013) · Lupus · doi:10.1177/0961203313500368 · Cited by 21 · cited 4×
“(CIA) [8, 9], fluorescence enzyme immunoassay (FEIA) [10, 11], and a multiplex fluorescent immunoassay (MFI) [12, 13].”
BackgroundInfluentialModer, K. G., Wener, M. H., Weisman, M. H., ISHIMORI, M. L., Wallace, D. J., Buckeridge, D. L., & Homburger, H. A. (2007) · PubMed · Cited by 20
González, D. A., Roces-Varela, A., Rodríguez, I. M., Vera, A. G., Sánchez, M. D., Esquivel, A. A., Rodríguez, C. C., & de León, A. C. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.09.003 · Cited by 18 · cited 11×
“The QUANTA Flash dsDNA (Inova Diagnostics Inc., San Diego, CA, USA) assay is a novel CIA that is used on the BIO-FLASH instrument (Biokit s.a., Barcelona, Spain).”
BackgroundMethodInfluentialHighlights on Novel Technologies for the Detection of Antibodies to Ro60, Ro52, and SS-B
Infantino, M. G., Bentow, C., Seaman, A., Benucci, M., Atzeni, F., Sarzi‐Puttini, P., Olivito, B., Meacci, F., Manfredi, M., & Mähler, M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/978202 · Cited by 18
Self-citationThe impact of biological treatments on the anti-dsDNA and anti-nucleosome tests
Infantino, M. G., Grossi, V., Benucci, M., Gobbi, F. L., Damiani, A., & Manfredi, M. (2017) · Lupus · doi:10.1177/0961203317709344 · Cited by 11
Self-citationDetermination of Antibodies to Double-Stranded RNA by Enzyme-Linked Immunosorbent Assay (ELISA)
Field, A., Davies, M. E. M., & TYTELL, A. A. (1980) · Experimental Biology and Medicine · doi:10.3181/00379727-164-40909 · Cited by 8 · cited 1×
“Additionally, the ribonucleic acid (RNA) can also constitute an antigen in SLE condition and its corresponding antibody reactivity can be linked to epitopes shared with DNA or not form a separate entity [6, 7].”
BackgroundShigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Research works printed but not linked: 1
- Hillebrand JJ, Bernelot Moens HJ, Mulder AH. Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus. 2013;22:1169–73. · DOI · Paper page
Cited by
Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus
Infantino, M., Nagy, E., Bizzaro, N., Fischer, K., Bossuyt, X., & Damoiseaux, J. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100139 · Cited by 38
Self-citationLaboratory evaluation of anti-dsDNA antibodies.
Cockx, M., Van Hoovels, L., De Langhe, E., Lenaerts, J., Thevissen, K., Persy, B., Bonroy, C., Vercammen, M., & Bossuyt, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.029 · Cited by 30
Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab146 · Cited by 30
“CLIFT (42, 47, 55, 68) and 5 studies for NOVA Lite CLIFT (44, 52, 55, 56, 67).”
InfluentialComparison of current methods for anti‐dsDNA antibody detection and reshaping diagnostic strategies
Infantino, M., Palterer, B., Previtali, G., Alessio, M., Villalta, D., Carbone, T., Platzgummer, S., Paura, G., Castiglione, C., Fabris, M., et al. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13220 · Cited by 20
Self-citationArévalo, B., Serafín, V., Sánchez-Paniagua, M., Montero‐Calle, A., Barderas, R., López-Ruíz, B., Campuzano, S., Yáñez‐Sedeño, P., & Pingarrón, J. M. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112233 · Cited by 20
Metadata
- Authors
- Infantino, M., Manfredi, M., Merone, M., Grossi, V., Benucci, M., Li Gobbi, F., Bandinelli, F., Damiani, A., & Soda, P.
- Affiliations
- Nuovo Ospedale San Giovanni di Dio (IT)
- Università Campus Bio-Medico (IT)
- Corresponding author
- Infantino, Maria
- Venue
- Immunologic Research
- Published
- 2018-04-05
- Volume
- 66
- Issue
- 3
- Pages
- 340-347
- ISSN
- 0257-277X (ISSN-L)
- 1559-0755
- OpenAlex
- W2795412599
- Semantic Scholar
- 6c8e1323d32be42d06475fd78c3e9611d6ab8bec
- Cited by
- 16
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Immunologic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- anti-dsDNA antibodies, systemic lupus erythematosus, assay standardization, analytical variability, inflammatory arthritis, biologic therapy, chemiluminescence immunoassay, indirect enzyme immunoassay, sensitivity and specificity, assay agreement
- MeSH terms
- Antibodies, Antinuclear, Arthritis, Rheumatoid, Crithidia, DNA, Fluorescent Antibody Technique, Humans, Immunoassay, Luminescent Measurements, Lupus Erythematosus, Systemic, Sensitivity and Specificity, Reproducibility of Results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.